Get the Daily Brief
Latest Biotech News
Multi‑omics maps immune drivers of pig‑to‑human kidney xenotransplant rejection
Researchers performed comprehensive multi‑omic profiling after transplanting a genetically edited pig kidney into a brain‑dead human donor and tracked immune dynamics over 61 days. The team...
BMS/J&J’s factor‑XI inhibitor fails key Phase‑3: milvexian trial stopped
Bristol Myers Squibb and Johnson & Johnson halted a Phase 3 trial of their factor‑XIa inhibitor milvexian for acute coronary syndrome after an interim analysis showed the drug was unlikely to meet...
Twist reframes reporting as AI‑driven drug discovery lifts revenues
Twist Bioscience reorganized its revenue reporting into a single 'DNA synthesis and protein solutions' segment as AI‑driven drug discovery increased cross‑product demand. CEO Emily Leproust cited...
Scientists immortalize bovine cells without genetic edits — cultivated beef barrier drops
A team at the Hebrew University of Jerusalem and Believer Meats reported a method to immortalize bovine cells without genetic modification, published in Nature. The investigators activated...
Magnetic microrobots navigate vasculature to release drugs with surgical precision
Researchers at ETH Zurich described a clinically oriented magnetically guided microrobotic system that navigates complex vasculature to place and dissolve drug‑loaded capsules at target sites,...
Merck shells out $9.2B for Cidara — buys late‑stage flu prophylactic
Merck agreed to acquire Cidara Therapeutics for $9.2 billion, paying $221.50 per share in cash to obtain CD388, a late‑stage, long‑acting antiviral designed to prevent seasonal influenza. Cidara’s...
Pfizer closes Metsera buyout — ends Novo’s late bid
Pfizer closed its takeover of obesity biotech Metsera after a contested bidding period, securing Metsera’s pipeline including a fast‑acting amylin analog alongside a long‑acting GLP‑1. The deal...
FDA sketches ‘plausible mechanism’ path: bespoke drugs get a roadmap
FDA leaders outlined a new regulatory framework to accelerate approvals for individualized and ultra‑rare therapies by allowing plausible‑mechanism evidence in lieu of traditional randomized...
FDA clears Kura’s ziftomenib — first menin inhibitor approved for NPM1‑mutant AML
The U.S. FDA approved Kura Oncology and Kyowa Kirin’s ziftomenib (Komzifti) for relapsed or refractory acute myeloid leukemia with NPM1 mutations, granting the drug full approval based largely on...
Multi‑omics of pig‑to‑human kidney transplant reveals immune drivers — rejection reversible
Researchers published comprehensive multi‑omic analyses following a gene‑edited pig kidney transplanted into a brain‑dead human recipient and tracked immune responses over 61 days. Teams...
Medicxi closes €500M fund V to back asset‑centric biotech creation
London‑based venture firm Medicxi raised €500 million for Fund V to finance asset‑centric biotech startups and selective later‑stage opportunities. The oversubscribed fund continues Medicxi’s...
Novartis’ GanLum meets Phase III goal — a new tool against resistant malaria
Novartis reported Phase III non‑inferiority results for GanLum (ganaplacide + lumefantrine), meeting WHO efficacy thresholds and showing high cure rates across study arms in sub‑Saharan Africa....
Magnetically guided microrobots pass large‑animal tests for targeted delivery
Researchers at ETH Zurich described a magnetically guided microrobotic platform that navigates vasculature and cerebrospinal spaces in large‑animal models to deliver localized drug payloads. The...
Ultra‑mild methylation sequencing overcomes DNA damage limits in archival samples
Researchers unveiled UMBS‑seq (Ultra‑Mild Bisulfite Sequencing), a gentler methylation assay that preserves degraded DNA while delivering accurate methylation calls—addressing long‑standing...
Biotech shakeups: layoffs, pivots and cash‑preserving restructurings hit small firms
Sensei Therapeutics announced a 65% workforce reduction and termination of three executive roles as it winds down development and explores strategic alternatives; the company retains a minimal...
Merck pays $9.2B for Cidara: bets on season-long flu biologic
Merck agreed to acquire Cidara Therapeutics for $9.2 billion in cash, securing rights to CD388, a late‑stage long‑acting antiviral designed to prevent seasonal influenza. The deal values Cidara at...
FDA clears Kura/Kyowa’s Komzifti — first menin inhibitor approved for NPM1 AML
The U.S. Food and Drug Administration approved ziftomenib (Komzifti), a selective oral menin inhibitor developed by Kura Oncology and Kyowa Kirin, for relapsed or refractory acute myeloid leukemia...
FDA unveils plausible‑mechanism pathway: roadmap for bespoke rare‑disease therapies
Top FDA officials outlined a new regulatory approach — dubbed the "plausible‑mechanism" or bespoke pathway — to accelerate approvals for individualized gene‑editing and personalized biologics when...
Multi‑omics maps rejection in pig‑to‑human kidney grafts — 61‑day physiology study
Researchers published comprehensive multi‑omic analyses following a genetically modified pig kidney transplanted into a brain‑dead human recipient and maintained for 61 days. Teams tracked tissue,...
Pfizer closes up to $10B Metsera deal — inside a high‑stakes bidding war
Pfizer completed its acquisition of obesity biotech Metsera for up to $10 billion, securing the company’s fast‑acting amylin analog and long‑acting GLP‑1 assets. The purchase ends a heated contest...